Calithera Biosciences (NASDAQ:CALA): Negative Stock Sentiment

September 14, 2018 - By Jacqueline McKee

Calithera Biosciences, Inc. (NASDAQ:CALA) Logo

Sentiment for Calithera Biosciences (NASDAQ:CALA)

Calithera Biosciences (NASDAQ:CALA) institutional sentiment decreased to 0.67 in 2018 Q2. Its down -0.24, from 0.91 in 2018Q1. The ratio has dropped, as 33 hedge funds increased or opened new equity positions, while 49 sold and decreased positions in Calithera Biosciences. The hedge funds in our partner’s database now possess: 18.33 million shares, down from 21.05 million shares in 2018Q1. Also, the number of hedge funds holding Calithera Biosciences in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 20 Reduced: 29 Increased: 19 New Position: 14.

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company has market cap of $169.14 million. The Company’s lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. It currently has negative earnings. The firm has a license agreement with Mars, Inc. to develop and commercialize SymbioscienceÂ’s portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors.

The stock decreased 2.08% or $0.1 during the last trading session, reaching $4.7. About 219,917 shares traded. Calithera Biosciences, Inc. (NASDAQ:CALA) has declined 69.23% since September 14, 2017 and is downtrending. It has underperformed by 84.85% the S&P500.

Analysts await Calithera Biosciences, Inc. (NASDAQ:CALA) to report earnings on November, 1. They expect $-0.41 earnings per share, down 141.18 % or $0.24 from last year’s $-0.17 per share. After $-0.09 actual earnings per share reported by Calithera Biosciences, Inc. for the previous quarter, Wall Street now forecasts 355.56 % negative EPS growth.

Franklin Street Advisors Inc Nc holds 0.06% of its portfolio in Calithera Biosciences, Inc. for 81,580 shares. Hikari Power Ltd owns 100,000 shares or 0.06% of their US portfolio. Moreover, Piermont Capital Management Inc. has 0.06% invested in the company for 38,400 shares. The California-based Ascend Capital Llc has invested 0.05% in the stock. Federated Investors Inc Pa, a Pennsylvania-based fund reported 1.89 million shares.

Another recent and important Calithera Biosciences, Inc. (NASDAQ:CALA) news was published by Nasdaq.com which published an article titled: “Calithera Biosciences to Participate in the Citi 13th Annual Biotech Conference and the Wells Fargo Healthcare …” on August 29, 2018.

Calithera Biosciences, Inc. (NASDAQ:CALA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.